Clinical Trials Logo

Clinical Trial Summary

Parkinson's disease is characterized by cardinal motor signs such as bradykinesia, tremor, rigidity and postural instability. In addition to these findings, motor freezing, gait disorders, posture disorders, decreased arm swings and loss of axial rotation are also seen. About 80% of the causes of falls in Parkinson's patients are due to postural instability and motor freezing, and patients' quality of life is significantly affected. In addition, gait disorders are common in advanced stages of Parkinson's Disease. Gait disorders decrease the quality of life by increasing the risk of falls, fractures and mortality. Therefore, the aim of this study is to observe the change in gait, foot pressure distribution and balance parameters of Parkinson's patients with and without motor deceleration compared to each other and healthy controls and to determine the relationship between these parameters.


Clinical Trial Description

Parkinson's disease is characterized by basic motor symptoms such as bradykinesia, tremor, rigidity and postural instability. In addition to these findings, motor freezing, gait disorders, posture disorders, decreased arm swings and loss of axial rotation are also seen. Restrictions in balance, mobility and activities of daily living due to motor disorders seen in Parkinson's Disease and related disability, addiction and decrease in quality of life occur. Approximately 80% of the causes of falls in Parkinson's patients are due to postural instability and motor freezing, and the quality of life of patients is significantly affected. Also, gait disturbances are common in advanced stages of Parkinson's Disease. Gait disorders reduce the quality of life by increasing the risk of falls, fractures and death. Therefore, the aim of this study is to observe the changes in the gait, foot pressure distribution and balance parameters of Parkinson's patients with and without motor retardation compared to each other and to healthy controls, and to determine the relationship between these parameters. This research is planned as two sub-work packages. Foot pressure distribution analysis and gait evaluation will be performed in the first sub-work package, and balance evaluation will be performed in the second sub-work package. From the results of this research, 2 separate articles will be written that evaluate the balance and foot pressure distribution analysis and gait separately. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05107531
Study type Observational
Source Hacettepe University
Contact
Status Completed
Phase
Start date September 10, 2021
Completion date February 5, 2022

See also
  Status Clinical Trial Phase
Completed NCT03665493 - Dopamine Effect on Inhibitory Control N/A
Completed NCT02227355 - Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease N/A
Completed NCT01026428 - A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Phase 1/Phase 2
Completed NCT00664157 - Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus N/A
Completed NCT04524143 - The Acute Effect of Cervical Mobilization in Parkinson's Disease N/A
Completed NCT04524182 - The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease N/A
Completed NCT00985517 - Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT01968031 - A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Phase 3
Completed NCT01970813 - Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease N/A
Completed NCT01221948 - Vercise Implantable Stimulator for Treating Parkinson's Disease Phase 2
Terminated NCT01028586 - MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) Phase 3
Completed NCT00239564 - Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease Phase 1/Phase 2
Completed NCT02240030 - Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Phase 3
Completed NCT00605683 - MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Phase 3
Completed NCT00400634 - Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease Phase 2
Completed NCT01227265 - Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) Phase 3
Completed NCT02565628 - PF-06669571 In Subjects With Idiopathic Parkinson's Disease Phase 1
Completed NCT01617135 - Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes Phase 2
Completed NCT01606670 - Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
Terminated NCT00261781 - Walking Capacity in Parkinson's Disease (PD-Walk) N/A